Tian, X., Lu, X., Zhang, H., Ye, D. (2026). A kidney-sparing approach using disitamab vedotin plus toripalimab for high-risk upper urinary tract urothelial carcinoma in patients with impaired renal function: Preliminary results from a phase II trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e16607